- Home
- TERN vs LAZ Comparison
TERN vs LAZ Comparison
Compare TERN & LAZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TERN | LAZ |
|---|---|---|
| Founded | 2017 | 1848 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 5.3B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | TERN | LAZ |
|---|---|---|
| Price | $42.72 | $48.08 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 10 | 8 |
| Target Price | $48.60 | ★ $55.38 |
| AVG Volume (30 Days) | ★ 1.7M | 1.0M |
| Earning Date | 04-17-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.07% |
| EPS Growth | ★ 11.81 | N/A |
| EPS | N/A | ★ 2.17 |
| Revenue | N/A | ★ $3,186,466,000.00 |
| Revenue This Year | N/A | $15.81 |
| Revenue Next Year | N/A | $12.49 |
| P/E Ratio | ★ N/A | $22.66 |
| Revenue Growth | N/A | ★ 1.48 |
| 52 Week Low | $1.87 | $31.97 |
| 52 Week High | $48.26 | $58.75 |
Technical Indicators
Market Signals| Indicator | TERN | LAZ |
|---|---|---|
| Relative Strength Index (RSI) | 68.48 | 38.37 |
| Support Level | $39.15 | $47.92 |
| Resistance Level | $48.26 | $52.07 |
| Average True Range (ATR) | 2.08 | 2.48 |
| MACD | 0.28 | -0.44 |
| Stochastic Oscillator | 96.50 | 16.12 |
Price Performance
Historical ComparisonAbout TERN Terns Pharmaceuticals Inc.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.
About LAZ Lazard Inc.
Lazard Inc has a storied history that can be traced back to 1848. The company's revenue is fairly evenly split between financial advisory, such as acquisition and restructuring advisory, and asset management. The company's asset management business is primarily driven by equities (over 80% of assets under management), has an international focus, and targets institutional clients. By geography, the company earns approximately 60% of revenue in the Americas, 35% in EMEA, and 5% in Asia-Pacific. Lazard has offices across more than 20 countries and over 3,000 employees.